Tucson, AZ, May 28, 2016 --(PR.com
)-- Evan Unger, MD, President and CEO of NuvOx Pharma, a Tucson based biotechnology company, announced that the company has been awarded a grant from the National Cancer Institute to develop an ultrasound contrast agent to diagnose pancreatic cancer. The Phase I Small Business Technology Transfer (STTR) grant is a joint development project between NuvOx and Stanford University. The two principal investigators on the project are Drs. Unger and Juergen Willmann, MD, Chief of Body Imaging, Professor of Radiology, Stanford University, School of Medicine.
There are currently about 50,000 new cases of pancreatic cancer each year in the US and more than 40,000 deaths. The overall 5-year survival rate for pancreatic cancer is less than 5% because most cancers have already spread at the time of diagnosis. Dr. Willmann’s lab discovered a biomarker that is expressed early in the development of pancreatic cancer that can potentially be used to detect early stage pancreatic cancer. Dr. Willmann said, “I am very pleased to work on this project with NuvOx. Dr. Unger previously developed the #1 selling ultrasound contrast agent, Definity. The group at NuvOx are experts in nanotechnology, together we hope to develop a new technology to detect early stage pancreatic cancer while it is still curable.”
Disclaimer: Certain statements in this release may constitute “forward-looking statements.” When used in this release, words like “may,” “will,” “can,” “should,” “expect,” “anticipate,” “believe,” “project,” or “intend” and other similar expressions are intended to identify forward-looking statements. Statements regarding future events and developments and future performance, as well as our expectations, beliefs, plans, or projections, are forward-looking statements which reflect only our predictions, assumptions, and estimates regarding future events and circumstances. Actual events or results may differ substantially as a result of risks and uncertainties facing us. The forward-looking statements are based on current expectations as of the date of these statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information, or otherwise.